
Amit Verma

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1241199/publications.pdf Version: 2024-02-01



AMIT VEDMA

#	Article	IF	CITATIONS
1	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances, 2022, 6, 1152-1161.	5.2	13
2	VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. Nature Cell Biology, 2022, 24, 290-298.	10.3	19
3	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	30.7	19
4	A needed boost against COVID-19 in lymphoma. Nature Cancer, 2022, 3, 526-527.	13.2	1
5	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of Clinical Oncology, 2021, 39, 1001-1009.	1.6	22
6	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	6.2	27
7	Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer Journal, 2021, 11, 152.	6.2	17
8	Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis. Leukemia, 2020, 34, 1689-1693.	7.2	12
9	The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. Leukemia and Lymphoma, 2020, 61, 2453-2465.	1.3	1
10	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood, 2020, 135, 191-207.	1.4	40
11	HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3529-3535.	1.3	15
12	Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. Leukemia and Lymphoma, 2019, 60, 3132-3137.	1.3	5
13	Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease. Nature Communications, 2019, 10, 2461.	12.8	59
14	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
15	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	9.4	41
16	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	5.2	12
17	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 2019, 25, 103-110.	30.7	169
18	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. ELife, 2019, 8, .	6.0	103

AMIT VERMA

#	Article	IF	CITATIONS
19	Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. Journal of Biological Chemistry, 2017, 292, 837-846.	3.4	43
20	Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. Leukemia and Lymphoma, 2016, 57, 2452-2455.	1.3	2
21	Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle, 2014, 13, 3320-3327.	2.6	26
22	Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica, 2014, 99, 930-936.	3.5	59
23	Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes. Seminars in Hematology, 2013, 50, 16-37.	3.4	42